DLL3 and neoplasm: Tarlatamab (AMG 757) is the first DLL3-targeting bispecific T-cell engager therapy that activates a patient’s T cells to attack DLL3-expressing tumor cells, which is a bispecific T-cell engager molecule that binds both DLL3 and CD3, leading to T-cell-mediated tumor lysis [8].